The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
A Double-blind, Placebo-Controlled Dose-Response Comparison of Intramuscular Olanzapine and Haloperidol in the Treatment of Acute Agitation in Schizophrenia
Abstract
BACKGROUND: An intramuscular (IM) formulation of olanzapine has been developed because there are no rapid-acting IM atypical antipsychotic drugs currently available in the United States for treating acute agitation in patients with schizophrenia. METHODS: Recently hospitalized acutely agitated patients with schizophrenia (N = 270) were randomized to receive 1 to 3 IM injections of olanzapine (2.5, 5.0, 7.5, or 10.0 mg), haloperidol (7.5 mg), or placebo within 24 hours. A dose-response relationship for IM olanzapine in the reduction of agitation was assessed by measuring the reduction in Positive and Negative Syndrome Scale Excited Component (PANSS-EC) scores 2 hours after the first injection. Safety was assessed by recording adverse events and with extrapyramidal symptom scales and electrocardiograms at 24 hours after the first injection. RESULTS: Olanzapine exhibited a dose-response relationship for reduction in agitation (F(1,179)= 14.4; P<.001). Mean PANSS-EC reductions 2 hours after the first injection of olanzapine (2.5 mg = -5.5; 5.0 mg = -8.1; 7.5 mg = -8.7; 10.0 mg = -9.4) were superior to those with placebo (-2.9; P =.01 vs olanzapine at 2.5 mg; P<.001 for each other olanzapine dose) but not with haloperidol (-7.5). A dose of 5.0, 7.5, or 10.0 mg of olanzapine caused a greater reduction in agitation than placebo 30 minutes after the first injection. There were no differences between treatment groups for hypotension, the most frequently reported adverse event, or for clinically relevant changes in the QTc interval. There was a greater incidence of treatment-emergent parkinsonism during treatment with IM haloperidol (16.7%) than with 2.5 (P =.03), 5.0 (P =.03), or 7.5 mg (P =.01) of IM olanzapine (0%) or with placebo (0%) (P =.01). CONCLUSIONS: Intramuscular olanzapine at a dose of 2.5 to 10.0 mg per injection exhibits a dose-response relationship in the rapid treatment of acute agitation in patients with schizophrenia and demonstrates a favorable safety profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
(1976) · Medical Entomology and Zoology · Cited by 8,899
Statistical methods in cancer research. Volume I - The analysis of case-control studies.
Breslow, N. E., & Day, N. E. (1980) · PubMed · Cited by 4,988
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
Categorical Data Analysis Using the SAS System
(1996) · Technometrics · doi:10.1080/00401706.1996.10484575 · Cited by 1,869
A Survey of Drug-Induced Extrapyramidal Reactions
Ayd, F. J. (1961) · JAMA · doi:10.1001/jama.1961.03040120016004 · Cited by 753
Tran, P. V., Hamilton, S. H., Kuntz, A. J., Potvin, J. H., Andersen, S. W., Beasley, C. J., & Tollefson, G. D. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00010 · Cited by 715
QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients
Reilly, J., Ayis, S., Ferrier, I., Jones, S., & Thomas, S. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02035-3 · Cited by 602
Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses
Baldessarini, R. J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800250095013 · Cited by 545
Pyramidical Model of Schizophrenia
Kay, S. R., & Sevy, S. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.3.537 · Cited by 444
Categorical Data Analysis Using the SAS System
Ziegel, E. R., Stokes, M., Davis, C., & Koch, G. (1996) · Technometrics · doi:10.2307/1271334 · Cited by 389
VOLAVKA, J. (1996) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199609000-00012 · Cited by 327
Beasley, C. M., Hamilton, S. H., Crawford, A. M., Dellva, M. A., Tollefson, G. D., Tran, P. V., Blin, O., & Beuzen, J.-N. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00392-6 · Cited by 277
Respiratory Depression by Midazolam and Diazepam
Forster, A., Gardaz, J.-P., Suter, P. M., & Gemperle, M. (1980) · Anesthesiology · doi:10.1097/00000542-198012000-00010 · Cited by 271
Compliance with antipsychotic drug treatment: influence of side effects
WW, F., U, M., V, G., & M, K. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb05859.x · Cited by 241
Cardiovascular Adverse Effects of Antipsychotic Drugs
Buckley, N. A., & Sanders, P. (2000) · Drug Safety · doi:10.2165/00002018-200023030-00004 · Cited by 235
Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified?
Lader, M. H. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00051-6 · Cited by 220
Pharmacologic activation of limbic structures and neuroimaging studies of emotions.
Beasley, C. M., Tollefson, G. D., & Tran, P. V. (1997) · PubMed · Cited by 197
The Neurobiology of Violence: An Update
Volavka, J. (1999) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.11.3.307 · Cited by 181
Tran, P. V., Dellva, M. A., Tollefson, G. D., Beasley, C. M., Potvin, J. H., & Kiesler, G. M. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0505 · Cited by 167
Self-citationSide effect profiles of new antipsychotic agents.
Casey, D. E. (1996) · PubMed · Cited by 163
Behavioral toxicity of antipsychotic drugs.
Putten, T. V., & Marder, S. R. (1987) · PubMed · Cited by 144
Rapid Treatment of Acute Psychotic Symptoms With High- and Low-Dose Haloperidol
Neborsky, R. J. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780270081011 · Cited by 134
Electrocardiographic changes in patients receiving neuroleptic medication
Warner, J. P., Barnes, T. R. E., & Henry, J. A. (1996) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1996.tb10653.x · Cited by 133
Pilowsky, L. S., RING, H. A., Shine, P. J., Battersby, M., & LADER, M. H. (1992) · The British Journal of Psychiatry · doi:10.1192/bjp.160.6.831 · Cited by 124
Effect of clorazepate on depressed mood in anxious patients.
Zung, W. W. K. (1987) · PubMed · Cited by 113
Rapid treatment of acute psychosis
Anderson, W. H., Kuehnle, J. C., & Catanzano, D. M. (1976) · American Journal of Psychiatry · doi:10.1176/ajp.133.9.1076 · Cited by 103
Risk factors in neuroleptic malignant syndrome. A case–control study
Viejo, L. F., Morales, V., Puñal, P., et al. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2003.02385.x · Cited by 89
Causes of Neuroleptic Noncompliance
Weiden, P. J., Shaw, E., & Mann, J. J. (1986) · Psychiatric Annals · doi:10.3928/0048-5713-19861001-07 · Cited by 86
Binder, R. L., & McNiel, D. E. (1999) · Psychiatric Services · doi:10.1176/ps.50.12.1553 · Cited by 82
Violence in psychiatric patients: The role of psychosis, frontal lobe impairment, and ward turmoil
KRAKOWSKI, M. I., & Czobor, P. (1997) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(97)90031-6 · Cited by 69
VIOLENT PATIENTS IN THE EMERGENCY SETTING
Citrome, L., & Volavka, J. (1999) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70126-x · Cited by 59
Some adverse effects of antipsychotics: prevention and treatment.
LADER, M. H. (1999) · PubMed · Cited by 48
Further Experience and Observations with Lorazepam in the Management of Behavioral Agitation
MODEM, J. G. (1986) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198612000-00026 · Cited by 15
Respiratory Distress with Use of Lorazepam in Mania
COHEN, S., & Khan, A. (1987) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198706000-00028 · Cited by 9
Cited by
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Wilson, M., Pepper, D., Currier, G., Holloman, G., & Feifel, D. (2012) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2011.9.6866 · Cited by 402
Dose Response and Dose Equivalence of Antipsychotics
Davis, J. M., & Chen, N. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117422.05703.ae · Cited by 358
QTc Prolongation, Torsades de Pointes, and Psychotropic Medications
Beach, S. R., Celano, C. M., Noseworthy, P. A., Januzzi, J. L., & Huffman, J. C. (2013) · Psychosomatics · doi:10.1016/j.psym.2012.11.001 · Cited by 345
Metadata
- Authors
- Breier, A., Meehan, K., Birkett, M., David, S., Ferchland, I., Sutton, V., Taylor, C. C., Palmer, R., Dossenbach, M., Kiesler, G., Brook, S., & Wright, P.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2002-05-01
- Volume
- 59
- Issue
- 5
- Pages
- 441
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2027198501
- Cited by
- 289
- References
- 36
- FWCI
- 10.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.